Cargando…

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA

Detalles Bibliográficos
Autores principales:	Smirnova, Svetlana, Al-Radi, Lyubov, Moiseeva, Tatyana, Gurjanova, Margaritta, Yakutik, Igor, Sudarikov, Andrey, Dvirnik, Valentina, Kovrigina, Alla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428851/ http://dx.doi.org/10.1097/01.HS9.0000975860.49623.86

Ejemplares similares

PB1791: ON THE ISSUE OF HOUSEKEEPING GENE PRIMER DESIGN FOR ADEQUATE ASSESSMENT OF THE EXPRESSION OF THE CHIMERIC TRANSCRIPTS.
por: Fevraleva, I., et al.
Publicado: (2022)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2244: FEATURES OF POLYCYTHEMIA VERA WITH THE JAK 2 EXON 12 MUTATION.
por: Soubortseva, Irina, et al.
Publicado: (2023)

PB2344: STR-LOCI ALLELE IMBALANCE AT 9P24.1 AND PD-L1 EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.
por: Abdurashidova, Runiza, et al.
Publicado: (2023)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

PB1885: THE ROLE OF PET CT IN HAIRY CELL LEUKEMIA
por: itchaki, G., et al.
Publicado: (2022)

PB1868: EXPERIENCE IN THE TREATMENT OF HAIRY CELL LEUKEMIA IN KAZAKHSTAN.
por: Kemelbekov, N., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

P1043: EFFICACY AND SAFETY OF TRAMETINIB IN ADULTS WITH LANGERHANS CELL HISTIOCYTOSIS AND ERDHEIM-CHESTER DISEASE
por: Latyshev, Vitalii, et al.
Publicado: (2023)

PB2069: A CASE OF HAIRY CELL LEUKEMIA PRESENTED AS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
por: Almeida, C., et al.
Publicado: (2022)

P033: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
por: Shupletsova, Irirna, et al.
Publicado: (2022)

PB2700: ANXIETY AND DEPRESSION IN HEMATOLOGICAL MALIGNANCIES PATIENTS: FOCUS ON TREATMENT ADHERENCE
por: Vybornykh, Dmitry E, et al.
Publicado: (2023)

PB2281: HOW TO AVOID FALSE-NEGATIVE AND FALSE-POSITIVE COVID-19 PCR TESTING
por: Fevraleva, I., et al.
Publicado: (2022)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

MEK inhibition with trametinib is a successful therapy in ganglioglioma
por: Daniel, Eliza Baird, et al.
Publicado: (2020)

PB2130: RATIONAL FOR METHOTREXATE USAGE FOR THE TREATMENT AND PREVENTION OF CNS INVOLVEMENT IN PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMAS.
por: Misyurina, A., et al.
Publicado: (2022)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

PB2167: NGS CLONALITY TESTING FOR A DIFFERENTIAL DIAGNOSIS OF MYCOSIS FUNGOIDES
por: Sidorova, Y., et al.
Publicado: (2022)

Structural basis for the action of the drug trametinib at KSR-bound MEK
por: Khan, Zaigham M., et al.
Publicado: (2020)

PB2041: EVALUATION OF THE PROGNOSTIC VALUE OF THROMBOPHILIA MARKERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Makarik, T., et al.
Publicado: (2022)

PB1962: COMPARISON OF EXPRESSION OF NSD2, CYCLIN D1 AND C-MAF BY PLASMA CELLS IN BONE MARROW AND BONE PLASMACYTOMA IN PATIENTS WITH PLASMA CELL MYELOMA
por: Mamaeva, E., et al.
Publicado: (2022)

PB2257: SARS-COV-2 VARIANTS DETECTED IN EMPLOYEES OF ONE MEDICAL CENTER
por: Biderman, B., et al.
Publicado: (2022)

PB2283: IN THE ERA OF IMMUNOPHENOTYPING AND MOLECULAR DIAGNOSTICS DOES MORPHOLOGY PLAY AN ESSENTIAL ROLE IN DIFFERENTIATING HAIRY CELL LEUKEMIA FROM ITS MIMICS?
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB1954: COMPARING STR PROFILES OF DNA ISOLATED FROM DIVERSE TUMOR SITES IN MULTIPLE MYELOMA
por: Firsova, M., et al.
Publicado: (2022)

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018)

Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
por: Caruana, Marco, et al.
Publicado: (2020)

PB2174: ON THE ROBUSTNESS OF THE BUCCAL EPITHELIUM FOR ASSESSING RECIPIENT DNA PROFILE IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Risinskaya, N., et al.
Publicado: (2022)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB1874: BTK GENE MUTATIONS IN RUSSIAN PATIENTS TREATED WITH IBRUTINIB: AS-PCR VERSUS NGS FOR ALLELIC LOAD ASSESSMENT
por: Likold, E., et al.
Publicado: (2022)

PB1792: NGS VS PCR FOR THE DETECTION OF NPM1 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA.
por: Severina, N., et al.
Publicado: (2022)

Targeting MEK in vemurafenib-resistant hairy cell leukemia
por: Caeser, Rebecca, et al.
Publicado: (2018)

PB2068: RETROSPECTIVE ANALYSIS OF HAIRY CELL LEUKEMIA (HCL) PATIENTS (PTS) TREATED WITH DIFFERENT MODALITIES AS FIRST LINE: REAL-LIFE EXPERIENCE OVER 20 YEARS IN KUWAIT.
por: Alhuraiji, A., et al.
Publicado: (2022)

Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib
por: Zhu, Jingxuan, et al.
Publicado: (2020)

The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats
por: Bömers, Jesper Peter, et al.
Publicado: (2022)

PB1837: ANTIBIOTICS; A POSSIBLE ALTERNATE TREATMENT OPTION FOR MYELOID LEUKEMIA
por: Maham, Syeda, et al.
Publicado: (2023)

PB2683: MODERN DIAGNOSTIC CAPABILITIES OF THE OPHTHALMOLOGICAL STATUS OF PATIENTS WITH ONCO-HEMATOLOGICAL DISEASES.
por: Yusef, Yusef N, et al.
Publicado: (2023)

PB1853: OUTCOMES REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY MANIFESTATIONS AFTER GEMTUZUMAB OZOGAMICIN THERAPY
por: Ayubova, Bella, et al.
Publicado: (2023)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pmqqohq1laafgpmrjhgjhl7bv3